

Australia and New Zealand In Vitro Diagnostics Market Report and Forecast 2024-2032

Market Report (7 days) | 2024-02-12 | 120 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$3699.00
- Five User License \$5699.00
- Corporate License \$7699.00

Report description:

Australia and New Zealand In Vitro Diagnostics Market Report and Forecast 2024-2032

Australia and New Zealand In Vitro Diagnostics Market Outlook

The Australia and New Zealand in vitro diagnostics market size is anticipated to grow at a CAGR of 5.4% during the forecast period of 2024-2032, driven by innovation in molecular diagnostics and increasing expenditures and investments in the healthcare domain across the region.

In Vitro Diagnostics: Introduction

The in vitro diagnostics (IVD) market is a dynamic segment of the healthcare industry, primarily focused on the manufacture and use of medical devices and technologies for testing samples like blood, tissue, and urine outside the human body. Driven by technological advancements, increasing prevalence of chronic diseases, and a growing emphasis on early disease detection and personalized medicine, the market is witnessing substantial growth, with key players continuously innovating to meet the evolving healthcare demands.

Key Trends in the Australia and New Zealand In Vitro Diagnostics Market

Continuous innovation in molecular diagnostics, point-of-care testing, and next-generation sequencing technologies are enhancing accuracy and reducing turnaround times. Growing emphasis on personalized treatment approaches is driving demand for specific and targeted diagnostic tests.

The increasing incidence of chronic diseases such as diabetes, cancer, and cardiovascular disorders is prompting a higher demand for regular monitoring and early diagnosis. There's heightened regulatory oversight to ensure the reliability and accuracy of diagnostic tests, especially in the wake of the global health crises.

Integration of AI and machine learning in diagnostic procedures is improving predictive analytics, data management, and result interpretation. The market is witnessing a rise in demand for home-based testing kits and devices for conditions like diabetes and fertility, driven by consumer preference for convenience and privacy.

Laboratories are increasingly adopting automation to enhance productivity, reduce errors, and manage high test volumes.

Increased health consciousness and awareness about preventive healthcare are leading to a rise in regular health check-ups and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

screenings.

Australia and New Zealand In Vitro Diagnostics Market Segmentation

Market Breakup by Technology

- Clinical Chemistry
- Molecular Diagnostics
- Immuno Diagnostics
- Hematology
- Others

Market Breakup by Product and Services

- Instruments
- Reagents and Kits
- Services
- Data Management Software

Market Breakup by Applications

- Infectious Disease
- Diabetes
- Cancer/Oncology
- Cardiology
- Autoimmune Disease
- Other Applications

Market Breakup by End User

- Diagnostic Laboratories
- Hospitals and Clinics
- Academic Institutes
- Point-of-Care Testing centers
- Others

Market Breakup by Country

- Australia
- New Zealand

Australia and New Zealand In Vitro Diagnostics Market Overview

In Australia, the in vitro diagnostics (IVD) market is marked by a strong emphasis on advanced technology integration and high-quality healthcare services. There's a growing trend towards personalized treatment, driving demand for genetic and molecular diagnostics to tailor therapies to individual patient profiles. The Therapeutic Goods Administration (TGA) ensures rigorous standards, influencing the introduction and quality of IVDs. Integration of digital solutions like AI and machine learning in diagnostic procedures is enhancing accuracy and efficiency. Also, there is a higher elderly population increases the prevalence of age-related diseases, boosting the demand for diagnostic services.

New Zealand's IVD market trends are characterized by an inclusive healthcare approach and a focus on sustainable practices. Government programs emphasizing early disease detection and routine screening are propelling the IVD market. There's a significant interest in adopting cutting-edge diagnostic technologies, including point-of-care testing devices, offering rapid results. Efforts to improve diagnostic services in remote areas, ensuring wider access to healthcare facilities. There is a growing emphasis on eco-friendly medical products and waste management practices in healthcare facilities, aligning with the country's environmental conservation goals. Australia and New Zealand

Australia and New Zealand In Vitro Diagnostics Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- BioMerieux SA
- F. Hoffmann-La Roche Ltd
- Becton, Dickinson and Company
- Bio-Rad Laboratories Inc.
- Abbott Laboratories, Inc.
- Siemens AG
- Thermo Fisher Scientific, Inc.
- QIAGEN N.V.
- Roche Diagnostics
- Danaher Corporation
- Agilent Technologies, Inc
- Quidel Corporation
- Diasorin S.P.A
- Illumina, Inc.
- Hologic, Inc

We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Australia and New Zealand In Vitro Diagnostics Market Overview
 - 3.1 Australia and New Zealand In Vitro Diagnostics Market Historical Value (2017-2023)
 - 3.2 Australia and New Zealand In Vitro Diagnostics Market Forecast Value (2024-2032)
- 4 Australia and New Zealand In Vitro Diagnostics Market Dynamics
 - 4.1 Market Drivers and Constraints
 - 4.2 SWOT Analysis
 - 4.3 Porter's Five Forces Model
 - 4.4 Key Demand Indicators
 - 4.5 Key Price Indicators
 - 4.6 Industry Events, Initiatives, and Trends
 - 4.7 Value Chain Analysis
- 5 Australia and New Zealand In Vitro Diagnostics Market Segmentation
 - 5.1 Australia and New Zealand In Vitro Diagnostics Market by Technology
 - 5.1.1 Market Overview
 - 5.1.2 Clinical Chemistry
 - 5.1.3 Molecular Diagnostics
 - 5.1.4 Immuno Diagnostics
 - 5.1.5 Hematology
 - 5.1.6 Others
 - 5.2 Australia and New Zealand In Vitro Diagnostics Market by Product and Services

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.2.1 Market Overview
- 5.2.2 Instruments
- 5.2.3 Reagents and Kits
- 5.2.4 Services
- 5.2.5 Data Management Software
- 5.3 Australia and New Zealand In Vitro Diagnostics Market by Applications
 - 5.3.1 Market Overview
 - 5.3.2 Infectious Disease
 - 5.3.3 Diabetes
 - 5.3.4 Cancer/Oncology
 - 5.3.5 Cardiology
 - 5.3.6 Autoimmune Disease
 - 5.3.7 Other Applications
- 5.4 Australia and New Zealand In Vitro Diagnostics Market by End User
 - 5.4.1 Market Overview
 - 5.4.2 Diagnostic Laboratories
 - 5.4.3 Hospitals and Clinics
 - 5.4.4 Academic Institutes
 - 5.4.5 Point-of-Care Testing centers
 - 5.4.6 Others
- 5.5 Australia and New Zealand In Vitro Diagnostics Market by Country
 - 5.5.1 Market Overview
 - 5.5.2 Australia
 - 5.5.3 New Zealand
- 6 Patent Analysis
 - 6.1 Analysis by Type of Patent
 - 6.2 Analysis by Publication year
 - 6.3 Analysis by Issuing Authority
 - 6.4 Analysis by Patent Age
 - 6.5 Analysis by CPC Analysis
 - 6.6 Analysis by Patent Valuation
 - 6.7 Analysis by Key Players
- 7 Grants Analysis
 - 7.1 Analysis by year
 - 7.2 Analysis by Amount Awarded
 - 7.3 Analysis by Issuing Authority
 - 7.4 Analysis by Grant Application
 - 7.5 Analysis by Funding Institute
 - 7.6 Analysis by NIH Departments
 - 7.7 Analysis by Recipient Organization
- 8 Funding Analysis
 - 8.1 Analysis by Funding Instances
 - 8.2 Analysis by Type of Funding
 - 8.3 Analysis by Funding Amount
 - 8.4 Analysis by Leading Players
 - 8.5 Analysis by Leading Investors
 - 8.6 Analysis by Geography

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9 Partnership and Collaborations Analysis
 - 9.1 Analysis by Partnership Instances
 - 9.2 Analysis by Type of Partnership
 - 9.3 Analysis by Leading Players
 - 9.4 Analysis by Geography
- 10 Regulatory Framework
 - 10.1 Regulatory Overview
- 11 Supplier Landscape
 - 11.1 BioMerieux SA
 - 11.1.1 Financial Analysis
 - 11.1.2 Product Portfolio
 - 11.1.3 Demographic Reach and Achievements
 - 11.1.4 Mergers and Acquisitions
 - 11.1.5 Certifications
 - 11.2 F. Hoffmann-La Roche Ltd
 - 11.2.1 Financial Analysis
 - 11.2.2 Product Portfolio
 - 11.2.3 Demographic Reach and Achievements
 - 11.2.4 Mergers and Acquisitions
 - 11.2.5 Certifications
 - 11.3 Becton, Dickinson and Company
 - 11.3.1 Financial Analysis
 - 11.3.2 Product Portfolio
 - 11.3.3 Demographic Reach and Achievements
 - 11.3.4 Mergers and Acquisitions
 - 11.3.5 Certifications
 - 11.4 Bio-Rad Laboratories Inc.
 - 11.4.1 Financial Analysis
 - 11.4.2 Financial Portfolio
 - 11.4.3 Demographic Reach and Achievements
 - 11.4.4 Mergers and Acquisitions
 - 11.4.5 Certifications
 - 11.5 Abbott Laboratories, Inc.
 - 11.5.1 Financial Analysis
 - 11.5.2 Product Portfolio
 - 11.5.3 Demographic Reach and Achievements
 - 11.5.4 Mergers and Acquisitions
 - 11.5.5 Certifications
 - 11.6 Siemens AG
 - 11.6.1 Financial Analysis
 - 11.6.2 Product Portfolio
 - 11.6.3 Demographic Reach and Achievements
 - 11.6.4 Mergers and Acquisitions
 - 11.6.5 Certifications
 - 11.7 Thermo Fisher Scientific, Inc.
 - 11.7.1 Financial Analysis
 - 11.7.2 Product Portfolio

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.7.3 Demographic Reach and Achievements
- 11.7.4 Mergers and Acquisitions
- 11.7.5 Certifications
- 11.8 QIAGEN N.V.
 - 11.8.1 Financial Analysis
 - 11.8.2 Product Portfolio
 - 11.8.3 Demographic Reach and Achievements
 - 11.8.4 Mergers and Acquisitions
 - 11.8.5 Certifications
- 11.9 Roche Diagnostics
 - 11.9.1 Financial Analysis
 - 11.9.2 Product Portfolio
 - 11.9.3 Demographic Reach and Achievements
 - 11.9.4 Mergers and Acquisitions
 - 11.9.5 Certifications
- 11.10 Danaher Corporation
 - 11.10.1 Financial Analysis
 - 11.10.2 Product Portfolio
 - 11.10.3 Demographic Reach and Achievements
 - 11.10.4 Mergers and Acquisitions
 - 11.10.5 Certifications
- 11.11 Agilent Technologies, Inc
 - 11.11.1 Financial Analysis
 - 11.11.2 Product Portfolio
 - 11.11.3 Demographic Reach and Achievements
 - 11.11.4 Mergers and Acquisitions
 - 11.11.5 Certifications
- 11.12 Quidel Corporation
 - 11.12.1 Financial Analysis
 - 11.12.2 Product Portfolio
 - 11.12.3 Demographic Reach and Achievements
 - 11.12.4 Mergers and Acquisitions
 - 11.12.5 Certifications
- 11.13 Diasorin S.P.A
 - 11.13.1 Financial Analysis
 - 11.13.2 Product Portfolio
 - 11.13.3 Demographic Reach and Achievements
 - 11.13.4 Mergers and Acquisitions
 - 11.13.5 Certifications
- 11.14 Illumina, Inc.
 - 11.14.1 Financial Analysis
 - 11.14.2 Product Portfolio
 - 11.14.3 Demographic Reach and Achievements
 - 11.14.4 Mergers and Acquisitions
 - 11.14.5 Certifications
- 11.15 Hologic, Inc
 - 11.15.1 Financial Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.15.2 Product Portfolio
- 11.15.3 Demographic Reach and Achievements
- 11.15.4 Mergers and Acquisitions
- 11.15.5 Certifications
- 12 Australia and New Zealand In Vitro Diagnostics Market - Distribution Model (Additional Insight)
 - 12.1 Overview
 - 12.2 Potential Distributors
 - 12.3 Key Parameters for Distribution Partner Assessment
- 13 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 14 Company Competitiveness Analysis (Additional Insight)
 - 14.1 Very Small Companies
 - 14.2 Small Companies
 - 14.3 Mid-Sized Companies
 - 14.4 Large Companies
 - 14.5 Very Large Companies
- 15 Payment Methods (Additional Insight)
 - 15.1 Government Funded
 - 15.2 Private Insurance
 - 15.3 Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Australia and New Zealand In Vitro Diagnostics Market Report and Forecast
2024-2032**

Market Report (7 days) | 2024-02-12 | 120 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3699.00
	Five User License	\$5699.00
	Corporate License	\$7699.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-05"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

